Nematode Infections: Filariases

Infectious Disease Clinics of North America

Volumn 26, Issue 2, 2012, Pages 359-381

  Knopp, Stefanie ^a,b   Steinmann, Peter ^a,b   Hatz, Christoph ^a,b,c   Keiser, Jennifer ^a,b   Utzinger, Jürg ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Control; Dracunculus medinensis; Epidemiology; Filariasis; Loa loa; Mansonella perstans; Onchocerca volvulus; Wuchereria bancrofti

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MEBENDAZOLE; MOXIDECTIN; SURAMIN;

BANCROFTIAN FILARIASIS; BRAIN DISEASE; BRUGIAN FILARIASIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMA; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DOSE RESPONSE; DRACUNCULIASIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; ERADICATION THERAPY; FILARIASIS; FUNCTIONAL DISEASE; HELMINTHIASIS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LOIASIS; LYMPHATIC FILARIASIS; MANSONELLIASIS; MICROFILARIASIS; MULTIPLE CYCLE TREATMENT; NEMATODE LIFE CYCLE STAGE; NONHUMAN; ONCHOCERCIASIS; PARASITE TRANSMISSION; RECOMMENDED DRUG DOSE; RETINA HEMORRHAGE; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

FILARIASIS; FILARICIDES; HUMANS;

EID: 84861466593     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.02.005     Document Type: Review

References (94)

1. Taylor M.J., Hoerauf A., Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010, 376:1175-1185.
2. Hotez P.J., Molyneux D.H., Fenwick A., et al. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006, 3:e102.
3. Klion A.D. Filarial infections in travelers and immigrants. Curr Infect Dis Rep 2008, 10:50-57.
4. Bockarie M.J., Molyneux D.H. The end of lymphatic filariasis?. BMJ 2009, 338:b1686.
5. Cupp E.W., Sauerbrey M., Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Trop 2011, 120(Suppl 1):S100-S108.
6. Molyneux D.H., Bradley M., Hoerauf A., et al. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003, 19:516-522.
7. Thylefors B., Alleman M. Towards the elimination of onchocerciasis. Ann Trop Med Parasitol 2006, 100:733-746.
8. Ottesen E.A. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 2006, 61:395-441.
9. Ottesen E.A., Hooper P.J., Bradley M., et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008, 2:e317.
10. CDC Progress toward global eradication of dracunculiasis, January 2010-June 2011. Morb Mortal Wkly Rep 2011, 60:1450-1453.
11. Boussinesq M. Loiasis. Ann Trop Med Parasitol 2006, 100:715-731.
12. Simonsen P.E., Onapa A.W., Asio S.M. Mansonella perstans filariasis in Africa. Acta Trop 2011, 120(Suppl 1):109-120.
13. WHO The global burden of disease: 2004 update 2008, World Health Organization, Geneva (Switzerland), p. 1-160.
14. Hoerauf A., Pfarr K., Mand S., et al. Filariasis in Africa-treatment challenges and prospects. Clin Microbiol Infect 2011, 17:977-985.
15. Nutman T.B., Miller K.D., Mulligan M., et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. N Engl J Med 1988, 319:752-756.
16. CDC Imported dracunculiasis-United States, 1995 and 1997. Morb Mortal Wkly Rep 1998, 47:209-211.
17. CDC CDC health information for international travel 2012. The Yellow Book 2011, Centers for Disease Control and Prevention, Atlanta (GA), p. 1-640.
18. Lipner E.M., Law M.A., Barnett E., et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007, 1:e88.
19. Greenaway C. Dracunculiasis (guinea worm disease). CMAJ 2004, 170:495-500.
20. Cairncross S., Muller R., Zagaria N. Dracunculiasis (Guinea worm disease) and the eradication initiative. Clin Microbiol Rev 2002, 15:223-246.
21. Richards FO, Ruiz-Tiben E, Hopkins DR. Dracunculiasis eradication and the legacy of the smallpox campaign: What's new and innovative? What's old and principled? (Presented at the Symposium on Smallpox Eradication: Lessons, Legacies & Innovations). Vaccine 2011, in press; doi: 10.1016/j.vaccine.2011.07.115.
22. CDC Progress toward global eradication of dracunculiasis, January 2009-June 2010. Morb Mortal Wkly Rep 2010, 59:1239-1242.
23. WHO Dracunculiasis eradication-global surveillance summary, 2010. Wkly Epidemiol Rec 2011, 86:189-204.
24. Genchi C., Rinaldi L., Mortarino M., et al. Climate and Dirofilaria infection in Europe. Vet Parasitol 2009, 163:286-292.
25. Pampiglione S., Rivasi F. Human dirofilariasis due to Dirofilaria (Nochtiella) repens: an update of world literature from 1995 to 2000. Parassitologia 2000, 42:231-254.
26. Bloch P., Simonsen P.E. Immunoepidemiology of Dracunculus medinensis infections I. Antibody responses in relation to infection status. Am J Trop Med Hyg 1998, 59:978-984.
27. Knopp S., Amegbo I.K., Hamm D.M., et al. Antibody and cytokine responses in Dracunculus medinensis patients at distinct states of infection. Trans R Soc Trop Med Hyg 2008, 102:277-283.
28. Magnussen P., Yakubu A., Bloch P. The effect of antibiotic- and hydrocortisone-containing ointments in preventing secondary infections in guinea worm disease. Am J Trop Med Hyg 1994, 51:797-799.
29. Ruiz-Tiben E., Hopkins D.R. Dracunculiasis (Guinea worm disease) eradication. Adv Parasitol 2006, 61:275-309.
30. WHO Certification of dracunculiasis eradication; criteria, strategies, procedures-a practical guide 1996, WHO/FIL/96.188 REV.1, World Health Organization, Geneva (Switzerland), p. 1-33.
31. WHO African Programme for Onchocerciasis Control: meeting of national task forces, September 2011. Wkly Epidemiol Rec 2011, 86:541-556.
32. APOC Final communiqué of the 11th session of the Joint Action Forum (JAF) of APOC 2005, African Programme for Onchocerciasis Control, Paris, Ouagadougou, p. 1-27.
33. Basáñez M.G., Pion S.D., Churcher T.S., et al. River blindness: a success story under threat?. PLoS Med 2006, 3:e371.
34. WHO Report from the 2009 InterAmerican Conference on Onchocerciasis: progress towards eliminating river blindness in the Region of the Americas. Wkly Epidemiol Rec 2010, 85:312-328.
35. Murdoch M.E., Asuzu M.C., Hagan M., et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002, 96:283-296.
36. Brattig N.W. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004, 6:113-128.
37. Saint Andre A., Blackwell N.M., Hall L.R., et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002, 295:1892-1895.
38. WHO Monthly report on dracunculiasis cases, January-December 2010. Wkly Epidemiol Rec 2011, 86:81-92.
39. WHO Global Programme to Eliminate Lymphatic Filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 2011, 86:377-388.
40. Molyneux D.H. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans R Soc Trop Med Hyg 2009, 103:338-341.
41. Udall D.N. Recent updates on onchocerciasis: diagnosis and treatment. Clin Infect Dis 2007, 44:53-60.
42. Churcher T.S., Pion S.D., Osei-Atweneboana M.Y., et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci U S A 2009, 106:16716-16721.
43. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008, 21:673-681.
44. Collins K. Profitable gifts: a history of the Merck Mectizan Donation Program and its implications for international health. Perspect Biol Med 2004, 47:100-109.
45. Peters D.H., Phillips T. Mectizan Donation Program: evaluation of a public-private partnership. Trop Med Int Health 2004, 9:4-15.
46. Thylefors B. The Mectizan Donation Program (MDP). Ann Trop Med Parasitol 2008, 102:39-44.
47. Richard-Lenoble D., Kombila M., Rupp E.A., et al. Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. Am J Trop Med Hyg 1988, 39:480-483.
48. Gardon J., Gardon-Wendel N., Demanga N., et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997, 350:18-22.
49. Boatin B.A., Richards F.O. Control of onchocerciasis. Adv Parasitol 2006, 61:349-394.
50. Cox F.E.G. History of human parasitology. Clin Microbiol Rev 2002, 15:595-612.
51. Witt C., Ottesen E.A. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001, 6:582-606.
52. Hoerauf A., Satoguina J., Saeftel M., et al. Immunomodulation by filarial nematodes. Parasite Immunol 2005, 27:417-429.
53. Palumbo E. Filariasis: diagnosis, treatment and prevention. Acta Biomed 2008, 79:106-109.
54. Gyapong J.O., Kumaraswami V., Biswas G., et al. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005, 6:179-200.
55. Joseph A., Mony P., Prasad M., et al. The efficacies of affected-limb care with penicillin diethylcarbamazine, the combination of both drugs or antibiotic ointment, in the prevention of acute adenolymphangitis during bancroftian filariasis. Ann Trop Med Parasitol 2004, 98:685-696.
56. WHO Managing morbidity and preventing disability in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly Epidemiol Rec 2011, 86:581-588.
57. Weil G.J., Ramzy R.M. Diagnostic tools for filariasis elimination programs. Trends Parasitol 2007, 23:78-82.
58. Weil G.J., Lammie P.J., Weiss N. The ICT Filariasis Test: a rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 1997, 13:401-404.
59. Ramzy R.M., Farid H.A., Kamal I.H., et al. A polymerase chain reaction-based assay for detection of Wuchereria bancrofti in human blood and Culex pipiens. Trans R Soc Trop Med Hyg 1997, 91:156-160.
60. Williams S.A., Laney S.J., Bierwert L.A., et al. Development and standardization of a rapid, PCR-based method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring the human prevalence of bancroftian filariasis. Ann Trop Med Parasitol 2002, 96:41-46.
61. Mladonicky J.M., King J.D., Liang J.L., et al. Assessing transmission of lymphatic filariasis using parasitologic, serologic, and entomologic tools after mass drug administration in American Samoa. Am J Trop Med Hyg 2009, 80:769-773.
62. Blum J., Wiestner A., Fuhr P., et al. Encephalopathy following Loa loa treatment with albendazole. Acta Trop 2001, 78:63-65.
63. Taylor M.J., Makunde W.H., McGarry H.F., et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005, 365:2116-2121.
64. Supali T., Djuardi Y., Pfarr K.M., et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008, 46:1385-1393.
65. WHO Fiftieth World Health Assembly. Elimination of lymphatic filariasis as a public health problem. WHA50.29 1997, World Health Organization, Geneva (Switzerland), p. 1-2.
66. WHO Progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis 2010, World Health Organization, Geneva (Switzerland), p. 1-93.
67. Mohammed K.A., Molyneux D.H., Albonico M., et al. Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol 2006, 22:340-344.
68. Schlemper B.R., Steindel M., Grisard E.C., et al. Elimination of bancroftian filariasis (Wuchereria bancrofti) in Santa Catarina state, Brazil. Trop Med Int Health 2000, 5:848-854.
69. Agrawal V.K., Sashindran V.K. Lymphatic filariasis in India: problems, challenges and new initiatives. MJAFI 2006, 62:359-362.
70. Stolk W.A., de Vlas S.J., Habbema J.D.F. Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 2006, 5:5.
71. Ottesen E.A. The global programme to eliminate lymphatic filariasis. Trop Med Int Health 2000, 5:591-594.
72. Ramzy R.M., El Setouhy M., Helmy H., et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 2006, 367:992-999.
73. Molyneux D.H. Elimination of transmission of lymphatic filariasis in Egypt. Lancet 2006, 367:966-968.
74. Grady C.A., de Rochars M.B., Direny A.N., et al. Endpoints for lymphatic filariasis programs. Emerg Infect Dis 2007, 13:608-610.
75. Ramaiah K.D., Vijay Kumar K.N., Ravi R., et al. Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Ann Trop Med Parasitol 2005, 99:243-252.
76. Michael E., Malecela-Lazaro M.N., Kazura J.W. Elimination of lymphatic filariasis. Lancet 2006, 368:362-363.
77. WHO Report of a WHO informal consultation on epidemiologic approaches to lymphatic filariasis elimination: initial assessment, monitoring and certification 1998, World Health Organization, WHO/FIL/99/196. Geneva (Switzerland), p. 1-35.
78. Michael E., Malecela-Lazaro M.N., Kabali C., et al. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions. Trends Parasitol 2006, 22:226-233.
79. Michael E., Gambhir M. Transmission models and management of lymphatic filariasis elimination. Adv Exp Med Biol 2010, 673:157-171.
80. WHO WHO position statement on integrated vector management to control malaria and lymphatic filariasis. Wkly Epidemiol Rec 2011, 13:121-128.
81. Padgett J.J., Jacobsen K.H. Loiasis: African eye worm. Trans R Soc Trop Med Hyg 2008, 102:983-989.
82. Wanji S., Tendongfor N., Esum M., et al. Heterogeneity in the prevalence and intensity of loiasis in five contrasting bioecological zones in Cameroon. Trans R Soc Trop Med Hyg 2003, 97:183-187.
83. Ridley J.W. Parasitology for medical and clinical laboratory professionals 2011, Delmar Cengage Learning, Florence (Italy). 1st edition.
84. Carbonez G., Van De Sompel W., Zeyen T. Subconjunctival Loa loa worm: case report. Bull Soc Belge Ophtalmol 2002, 283:45-48.
85. Carme B., Boulesteix J., Boutes H., et al. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 1991, 44:684-690.
86. Klion A.D., Massougbodji A., Horton J., et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 1993, 168:202-206.
87. Bradley M., Kumaraswami V. Essential tools-drugs and clinical drug trials. Am J Trop Med 2004, 71:7-11.
88. Zouré H.G., Wanji S., Noma M., et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011, 5:e1210.
89. WHO/TDR Guidelines for rapid assessment of Loa loa 2002, World Health Organization and Special Programme for Research and Training in Tropical Diseases (TDR), Geneva (Switzerland), p. 1-19.
90. Coulibaly Y.I., Dembele B., Diallo A.A., et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 2009, 361:1448-1458.
91. Bregani E.R., Rovellini A., Mbaidoum N., et al. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 2006, 100:458-463.
92. Asio S.M., Simonsen P.E., Onapa A.W. A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of Mansonella perstans infections in Uganda. Trans R Soc Trop Med Hyg 2009, 103:274-279.
93. Person B., Bartholomew L.K., Gyapong M., et al. Health-related stigma among women with lymphatic filariasis from the Dominican Republic and Ghana. Soc Sci Med 2009, 68:30-38.
94. Babu B.V., Mishra S., Nayak A.N. Marriage, sex, and hydrocele: an ethnographic study on the effect of filarial hydrocele on conjugal life and marriageability from Orissa, India. PLoS Negl Trop Dis 2009, 3:e414.